Literature DB >> 25813993

Tumor Regression After Brachytherapy for Choroidal Melanoma: Reduction of Thickness and Cross-Sectional Area by Shape and Regression Pattern.

Mamunur Rashid1, Jorma Heikkonen2, Tero Kivelä1.   

Abstract

PURPOSE: To model regression rate of thickness and cross-sectional area of choroidal melanomas after ruthenium and iodine brachytherapy by shape and regression pattern (RP).
METHODS: We enrolled 330 of 388 consecutive uveal melanomas from 2000 to 2008 and analyzed images from I3 System-ABD 10-MHz B-Scan at diagnosis and during a 3-year-long follow-up. We classified tumor shape by Collaborative Ocular Melanoma Study definitions and RP according to an earlier study. We plotted regression over time and compared thickness and cross-sectional area.
RESULTS: The observed RP by thickness was classified as decrease (D) in 43%, stable (S) in 5%, increase (I) in 1%, and other in 40% of eyes; main subpatterns were decrease-stable (DS) in 16% and zigzag in 10% of eyes. The corresponding percentages by area were 42%, 3%, 1%, 45%, 16%, and 14%. Regression pattern was discordant in 34% of eyes for thickness versus area. Area reduced faster than thickness when shape was oval to dome or mushroom and if RP was D. Pooled patterns D, DS, decrease-increase (DI), and zigzag corresponded with progressive but increasingly less pronounced regression for 3 years (56% by thickness and 69% by area), 2 years (50% and 52%), 6 months (29% and 33%), and 6 months (19% and 23%), respectively. First-order exponential decay function fitted thickness and area regression for every shape and for patterns D, DS, DI, and zigzag.
CONCLUSIONS: Heterogeneity in RP, variation in shape, and tumor cross-sectional area as an alternative measure must be considered when tumor regression rate is used in outcome analysis.

Entities:  

Mesh:

Year:  2015        PMID: 25813993     DOI: 10.1167/iovs.14-16322

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  9 in total

1.  Tumor-height regression rate after brachytherapy between choroidal melanoma gene expression profile classes: effect of controlling for tumor height.

Authors:  Kishan Gupta; Colin A McCannel; Mitchell Kamrava; James Lamb; Robert D Almanzor; Tara A McCannel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-24       Impact factor: 3.117

2.  Regression patterns of choroidal melanoma: After palladium-103 (103Pd) plaque brachytherapy.

Authors:  Abhilasha Maheshwari; Paul T Finger
Journal:  Eur J Ophthalmol       Date:  2018-05-22       Impact factor: 2.597

3.  Ultra-wide-field imaging of choroidal melanoma before and after proton beam radiation therapy.

Authors:  Angeliki Psomiadi; Gertrud Haas; Michael Edlinger; Nikolaos E Bechrakis; Georgios Blatsios
Journal:  Eur J Ophthalmol       Date:  2019-08-30       Impact factor: 2.597

4.  Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy.

Authors:  Rui Fang; Heng Wang; Yang Li; Yue-Ming Liu; Wen-Bin Wei
Journal:  BMC Ophthalmol       Date:  2021-03-16       Impact factor: 2.209

5.  Prognosis Prediction of Uveal Melanoma After Plaque Brachytherapy Based on Ultrasound With Machine Learning.

Authors:  Jingting Luo; Yuning Chen; Yuhang Yang; Kai Zhang; Yueming Liu; Hanqing Zhao; Li Dong; Jie Xu; Yang Li; Wenbin Wei
Journal:  Front Med (Lausanne)       Date:  2022-01-21

6.  Radiological and clinical findings in uveal melanoma treated by plaque interventional radiotherapy (brachytherapy): Visual atlas and literature review on response assessment.

Authors:  Bruno Fionda; Monica Maria Pagliara; Valentina Lancellotta; Carmela Grazia Caputo; Calogero Casà; Maria Grazia Sammarco; Elisa Placidi; Patrizia Cornacchione; Francesco Boselli; Roberto Iezzi; Cesare Colosimo; Luca Tagliaferri; Maria Antonietta Blasi
Journal:  J Contemp Brachytherapy       Date:  2022-02-04

7.  Ultrasound Biomicroscopy Documented Anterior Uveal Melanoma Regression after Ruthenium-106 Plaque Therapy.

Authors:  Biljana Kuzmanović Elabjer; Mladen Bušić; Andrej Pleše; Mirjana Bjeloš; Daliborka Miletić; Nenad Vukojević
Journal:  Ocul Oncol Pathol       Date:  2021-02-15

8.  Outcomes of I-125 brachytherapy for uveal melanomas depending on irradiation dose applied to the tumor apex - a single institution study.

Authors:  Joanna Kowal; Anna Markiewicz; Magdalena Dębicka-Kumela; Anna Bogdali; Boz Ena Romanowska-Dixon
Journal:  J Contemp Brachytherapy       Date:  2018-12-28

9.  Comparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas.

Authors:  Fariba Ghassemi; Shahab Sheibani; Mojtaba Arjmand; Hosein Poorbaygi; Emad Kouhestani; Siamak Sabour; Farhad Samiei; Akbar Beiki-Ardakani; Mahmood Jabarvand; Ali Sadeghi Tari
Journal:  Clin Ophthalmol       Date:  2020-02-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.